An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety ...

A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...

The Red Ribbon Club of Salesian College of Higher Education, in collaboration with the National Service Scheme (NSS) and the ...

A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, according to the results of a c ...

That's why scientists studying AIDS continue to search for weak spots in the virus's infection cycle. HIV inserts its genes into the host cell's nucleus in an unusual way. It doesn't import its ...

Nov. 25, 2024 — A new study reveals significant progress in the global fight against HIV/AIDS ... By targeting infected cells in the brain, drug may clear virus ... Proof-of-Concept Study ...

Protein crystallization at the SER-CAT beamline at Argonne’s Advanced Photon Source proved key to the discovery of a new HIV vaccine candidate.

Blog - A groundbreaking project to study potential HIV vaccines in several African countries has been derailed by an abrupt ...